Cytokinetics Incorporated (CYTK) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Cytokinetics Incorporated (NASDAQ: CYTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $62.03 (-1.52% 1D, market cap $8.76B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CYTK ranks #852 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CYTK carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CORT (Corcept Therapeutics Incorporated) holds a C grade (63/100 RQD, P/E 93.2x, ROIC 4.8%, cap $8.77B) and ARWR (Arrowhead Pharmaceuticals Inc.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 11.1%, cap $8.46B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).
Per CYTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001061983), Cytokinetics Incorporated generated $88.0M in revenue (+376.6% YoY), -$785.0M in net income, and -$534.8M in free cash flow against $1.42B in total assets and $246.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 0.45 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
20D Institutional Volume Accumulation (±6.5% realized swing band)
Capital intensity & 0% operating margin leave 16 pts on the table
While CYTK currently carries a cautious 28/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($66.67) and Max Pain ($65.13) forces dealer call-delta covering toward $92.73.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cytokinetics Incorporated (CYTK) slipped -1.52% to $62.03, trading at 13% of its 52-week range ($58.05 – $88.31). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Singapore report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Oral Abstract presentations and one poste
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Baron Health Care Fund Q3 2026 report highlights key contributors and detractors from portfolio performance. Read the full analysis for more details.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +376.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CYTK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CYTK. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Cytokinetics Incorporated (CYTK) ranks #852 by composite RQD confidence (28/100, grade E) and #122 by equity capitalization ($8.76B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. PTGX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with CYTK at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CYTK
ACTIVE
Cytokinetics Incorporated | E | 28/100 | — | — | -35.0% | -1.52% | $8.76B | Benchmark Subject |
| CORT Corcept Therapeutics Incorporated | C | 63/100 | 93.2x | 96.0% | 4.8% | -0.81% | $8.77B | /cort-vs-cytk → |
| ARWR Arrowhead Pharmaceuticals Inc. | D+ | 58/100 | — | — | 11.1% | -0.55% | $8.46B | /arwr-vs-cytk → |
| TGTX TG Therapeutics Inc. | C | 63/100 | 19.9x | 83.7% | 12.0% | -2.01% | $9.36B | /tgtx-vs-cytk → |
| PTGX Protagonist Therapeutics Inc. | C | 65/100 | — | — | -16.7% | -3.78% | $9.37B | /ptgx-vs-cytk → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytokinetics Incorporated (CYTK) reported GAAP revenue of $88.0M (+376.6% vs. FY2024 revenue of $18.5M , and +1069.2% cumulative change since FY2023) , GAAP net income of -$785.0M, operating cash flow of -$510.0M, and free cash flow of -$534.8M (-33.8% YoY). On the balance sheet, CYTK closed FY2025 with $1.42B in total assets against $246.4M in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $88.0M | -$785.0M | -$510.0M | -$534.8M | $1.42B | $246.4M |
| FY2024 (FY) | 2024-12-31 | $18.5M | -$589.5M | -$395.9M | -$399.8M | $1.40B | $93.2M |
| FY2023 (FY) | 2023-12-31 | $7.5M | -$526.2M | -$414.3M | -$414.7M | $4.84B | $1.13B |
As of 2026-11-03, Cytokinetics Incorporated (NASDAQ: CYTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $62.03 (-1.52% 1D, market cap $8.76B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CYTK ranks #852 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CYTK carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CORT (Corcept Therapeutics Incorporated) holds a C grade (63/100 RQD, P/E 93.2x, ROIC 4.8%, cap $8.77B) and ARWR (Arrowhead Pharmaceuticals Inc.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 11.1%, cap $8.46B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).
Per CYTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001061983), Cytokinetics Incorporated generated $88.0M in revenue (+376.6% YoY), -$785.0M in net income, and -$534.8M in free cash flow against $1.42B in total assets and $246.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CYTK last traded at $62.03 (-1.52% on volume of 1,561,104 shares), positioning the stock -6.96% below its 50-day simple moving average ($66.67) and -11.49% below its 200-day simple moving average ($70.08). Across its 52-week range of $58.05 to $88.31, CYTK sits at the 13.2% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($58.00 to $66.06).
Cytokinetics Incorporated (CYTK) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $62.03 (-1.52% 1D, market capitalization $8.76B).
Cytokinetics Incorporated (CYTK) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue across the three periods in the SEC financials rose from $7.5M to $18.5M to $88.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cytokinetics Incorporated (CYTK) reported $88.0M in annual revenue (up from $18.5M in FY2024, +376.6% YoY) and -$785.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($7.5M revenue, -$526.2M net income) through FY2025, CYTK scaled operating cash flow to -$510.0M and free cash flow to -$534.8M, backed by $1.42B in total assets against $246.4M in total debt.
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — Investors should note the absence of mapped ripple effects is a gap in the data, not evidence that none exist.
Real-time company headlines, analyst actions, and sector developments for Cytokinetics Incorporated (CYTK) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Oral Abstract presentations and one poste
Picked up a starter position in CYTK in my $100K Virtual Cash book at $62.99. Scale of an $8.8B market capitalization with a 52-week high of $88.31 offers room for re-rating if revenue growth continues from $7.5M to $88.0M.. Trading inside a $58.05–$88.31 52-week range with -6.08% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
@BreakoutHunter Agree on the RQD 28/100 quality, though with 0.87 beta I'm scaling in with half-size at $62.99 and keeping dry powder in case we test $58.58.
Careful chasing CYTK at $62.99. A -35% ROIC, -6.08% FCF yield, and Altman Z of 0.45 signal weak cash generation and distress-range balance sheet risk.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $52.91 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: